cold
current
number
addit
antigen
chang
epidem
viru
strain
occur
influenza
necessit
annual
reformul
administr
vaccin
thu
need
exist
effect
antivir
agent
articl
review
antivir
use
prevent
treatment
respiratori
viral
infect
addit
discuss
proven
clinic
valu
see
tabl
l
conclud
briefli
consid
agent
approach
investig
interest
amantadin
hydrochlorid
first
antivir
agent
licens
treatment
respiratori
viru
infect
unit
state
specif
inhibit
replic
influenza
virus
symmetr
tricycl
amin
fig
la
given
oral
prophylact
efficaci
human
influenza
viru
infect
exact
mechan
action
amantadin
defin
appear
inhibit
earli
stage
replic
possibl
uncoat
viru
within
one
propos
mechan
action
relat
rais
ph
within
lysosom
possibl
interf
low
phmediat
event
although
amantadin
readili
concentr
lysosom
mammalian
cell
cellassoci
amantadin
appear
contribut
significantli
antivir
n
l
furthermor
nonspecif
effect
lysosom
ph
would
explain
amantadin
restrict
spectrum
activ
genet
studi
indic
suscept
human
influenza
virus
low
concentr
pg
per
ml
amantadin
confer
rna
segment
code
matrix
protein
viru
recent
evid
indic
singl
amino
acid
chang
transmembran
portion
protein
lead
amantadin
r
e
ne
amantadin
rimantadin
hydrochlorid
hydrochlorid
although
high
concentr
yg
per
ml
greater
inhibitori
virus
low
concentr
pg
per
ml
less
inhibit
influenza
plaqu
reduct
assay
per
cent
inhibitori
concentr
amantadin
rang
pg
per
ml
common
influenza
isol
mice
amantadin
given
subcutan
intraperiton
oral
viru
challeng
provid
dosedepend
protect
death
inflenza
therapeut
activ
observ
mice
treatment
begun
late
hour
infect
aerosol
amantadin
efficaci
intraperiton
administr
mice
high
concentr
pg
per
ml
achiev
human
convent
dose
lymphocyt
transform
respons
mitogen
specif
antigen
vitro
high
dose
teratogen
certain
laboratori
anim
amantadineresist
influenza
virus
recov
laboratori
condit
viru
passag
presenc
amantadin
experiment
avian
influenza
amantadineand
rimantadineresist
virus
isol
drugtreat
bird
bird
abl
infect
caus
ill
contact
bird
receiv
amantadin
prophylaxi
although
case
drug
resist
isol
report
person
receiv
amantadin
prophylaxi
therapi
monitor
drug
suscept
respiratori
virus
assum
increas
import
use
respiratori
antivir
increas
resist
virus
reportedli
isol
nondrug
expos
patient
amantadin
wellabsorb
oral
administr
time
peak
plasma
level
averag
hour
steadyst
level
obtain
within
measur
amantadin
concentr
achiev
ga
liquid
chromatographi
electron
captur
flame
ioniz
detect
administr
mg
daili
divid
dose
steadyst
peak
trough
plasma
concentr
healthi
adult
averag
pg
per
pg
per
respect
longterm
administr
mg
per
kg
per
day
children
cystic
fibrosi
mean
plasma
concentr
kg
per
ml
detect
salivari
nasal
mucu
concentr
similar
mous
lung
greater
concentr
found
blood
follow
oral
drug
administr
one
report
amantadin
concentr
autopsi
lung
tissu
infant
immunodefici
pg
per
ml
serum
cncentrat
despit
high
concentr
viral
replic
elimin
approxim
per
cent
oral
administ
amantadin
recov
unmetabol
urin
excret
glomerular
filtrat
probabl
tubular
seret
mean
plasma
halflif
hour
rang
hour
healthi
young
adult
allow
dose
twice
daili
plasma
halflif
increas
renal
insuffici
day
anur
patient
agerel
decreas
renal
clearanc
higher
blood
level
also
seen
consequ
dose
reduct
indic
reduc
risk
sideeffect
small
portion
drug
remov
hemodialyi
occurr
doserel
sideeffect
may
respons
part
slow
accept
clinician
amantadin
effect
antiinfluenza
agent
central
nervou
system
advers
effect
includ
nervous
lightheaded
difficulti
concentr
insomnia
fatigu
report
per
cent
receiv
mg
per
day
loss
appetit
nausea
also
occur
infreq
longterm
prophylaxi
studi
use
amantadin
mg
daili
excess
dropout
rate
due
drug
sideeffect
rang
per
tabl
uncontrol
prophylaxi
trial
involv
resid
mental
institut
per
cent
clinic
manifest
compat
advers
effect
per
cent
increas
seizur
activ
rel
high
dosag
mg
per
kg
per
day
one
third
colleg
student
take
mg
daili
day
one
studi
complain
difficulti
concentr
lightheaded
per
cent
complet
cours
wherea
anoth
studi
similar
popul
found
complet
complianc
despit
minor
symptom
dose
mg
per
day
associ
high
rate
advers
complaint
decreas
psychomotor
perform
test
sustain
attent
problemsolv
neurotox
common
plasma
concentr
kg
per
mlsl
concomit
administr
antihistaminel
anticholin
r
g
c
confus
auditori
visual
hallucin
occur
toxic
level
patient
renal
failurelo
seriou
neurolog
reaction
may
transient
revers
physstigmin
aerosol
administr
amantadin
gener
welltoler
caus
mild
local
sideeffect
rhinorrhea
nasal
irrit
healthi
revers
deterior
pulmonari
function
associ
cough
wheez
may
occur
patient
preexist
airway
abnorm
number
control
blind
studi
document
efficaci
oral
amantadin
prophylaxi
treatment
experiment
induc
natur
influenza
infect
amantadin
mg
per
day
approxim
per
cent
effect
prevent
natur
acquir
influenza
taken
durat
outbreak
commun
usual
see
tabl
amantadin
recipi
experi
subclin
infect
manifest
seroconvers
desir
featur
chemoprophylaxi
would
protect
reinfect
strain
amantadin
prophylaxi
appear
effect
prevent
nosocomi
infect
hospit
institut
among
household
famili
contact
amantadin
effect
agent
treatment
uncompl
influenza
begun
within
hour
onset
symptom
dosag
mg
per
day
effect
decreas
height
durat
fever
viral
shed
time
subject
improv
fig
one
studi
colleg
student
found
amantadin
treatment
reduc
number
miss
class
compar
anoth
studi
colleg
student
compar
amantadin
aspirin
treatment
influenza
found
rapid
deferves
among
aspirin
recipi
amantadin
recipi
significantli
rapid
symptom
improv
certain
abnorm
peripher
airway
function
also
improv
rapidli
amantadin
recipi
higher
dose
amantadin
mg
per
day
use
uncontrol
condit
treat
influenza
log
efficaci
amantadin
treat
sever
influenza
complic
establish
intermitt
aerosol
amantadin
limit
therapeut
effect
uncompl
influenza
infect
use
aerosol
amantadin
achiev
high
level
respiratori
secret
evalu
influenza
pneumonia
tabl
detail
discuss
prophylaxi
strategi
publish
center
diseas
control
usual
adult
dose
amantadin
prophylaxi
treatment
mg
per
day
oral
either
singl
twice
daili
administr
split
dose
may
decreas
incid
sideeffect
durat
administr
treatment
usual
day
prevent
durat
use
depend
specif
prophylaxi
strategi
exampl
week
conjunct
immun
week
season
prophylaxi
amantadin
dosag
must
decreas
elderli
ing
daili
renal
insuffici
creatinin
clearanc
less
ml
per
minut
nonelderli
person
activ
seizur
disord
appear
increas
risk
seizur
activ
also
given
reduc
dosag
exampl
mg
per
day
rimantadin
rimantadin
hydrochlorid
see
fig
lb
deriv
amantadin
also
specif
antiinfluenza
activ
similar
amantadin
rimantadin
believ
block
late
step
intracellular
uncoat
influenza
viru
preclin
studi
rimantadin
appear
greater
intrins
antivir
activ
rimantadin
concentr
requir
caus
per
cent
inhibit
influenza
viru
plaqu
format
rang
pg
per
compar
amantadin
rimantadin
produc
significantli
longer
protect
influenza
virusinduc
cytopath
effect
ferret
tracheal
ciliat
epithelium
exhibit
compar
protect
effect
fourto
eightfold
lower
concentr
high
concentr
pg
per
ml
rimantadin
toxic
uninfect
epithelium
amantadin
mice
subcutan
rimantadin
greater
therapeut
efficaci
influenza
equimolar
dose
prophylact
intraperiton
rimantadin
begin
hour
prior
viru
inocul
result
lower
pulmonari
viru
titer
less
sever
lung
lesion
diminish
antibodi
respons
decreas
capabl
transmit
infect
contact
anim
compar
amantadin
c
e
b
l
passag
influenza
viru
presenc
rimantadin
lead
develop
resist
one
studi
found
vitro
passag
viru
presenc
amantadin
result
resist
amantadin
slight
resist
rimantadin
wherea
passag
presenc
rimantadin
result
mark
resist
amantadin
slight
resist
rimantadin
jo
rimantadineresist
virus
isol
bird
treat
recent
rimantadin
treatment
children
associ
prolong
viral
shed
recoveri
resist
despit
structur
similar
see
fig
l
signific
differ
exist
amantadin
rimantadin
kinet
man
rimantadin
longer
plasma
halflif
lower
plasma
concentr
differ
metabol
amantadin
rimantadin
good
oral
bioavail
rel
slow
absorpt
time
peak
plasma
level
steadyst
young
adult
given
dosag
mg
twice
daili
peak
plasma
concentr
approxim
pg
per
elderli
popul
receiv
mg
twice
daili
month
peak
steadyst
plasma
level
averag
pg
per
ml
healthi
adult
plasma
halflif
averag
hour
rimantadin
undergo
extens
metabol
subsequ
renal
elimin
metabolit
less
per
cent
parent
drug
excret
unchang
urin
elimin
halflif
increas
per
cent
dialysi
patient
hemodialysi
remov
signific
amount
rimantadin
rimantadin
concentr
determin
ga
chromatographi
use
method
similar
amantadin
modifi
initi
derivat
step
follow
singl
dose
maximum
nasal
mucu
concentr
rimantadin
amantadin
similar
ratio
nasal
mucu
plasma
concentr
twofold
higher
rimantadin
find
suggest
rimantadin
may
concentr
respiratori
secret
result
could
explain
rimantadin
compar
efficaci
despit
lower
plasma
concentr
amantadin
toxic
equival
dosag
mg
per
day
rimantadin
associ
fewer
sideeffect
amantadin
repres
major
clinic
advantag
rimantadin
particular
central
nervou
system
toxic
uncommon
recipi
rimantadin
mg
per
withdraw
due
advers
effect
occur
less
often
see
tabl
dosag
mg
per
day
day
per
cent
rimantadin
recipi
consid
work
perform
impair
compar
per
cent
amantadin
recipi
aerosol
rimantadin
associ
unpleas
tast
smell
nasal
irrit
prophylact
therapeut
efficaci
rimantadin
similar
amantadin
natur
occur
influenza
infect
studi
conduct
dosag
mg
per
day
although
report
suggest
littl
mg
per
day
effect
dosag
mg
per
day
approxim
per
cent
effect
prevent
laboratorydocu
influenza
ill
see
tabl
among
children
receiv
prophylaxi
rimantadin
mg
per
kg
per
day
reduc
influenza
infect
rate
per
cent
provid
complet
protect
influenza
ill
previous
vaccin
nurs
home
resid
rimantadin
per
cent
effect
prevent
influenzalik
ill
compar
placebo
one
studi
compar
rimantadin
amantadin
given
mg
twice
daili
treatment
uncompl
influenza
found
slightli
rapid
improv
first
hour
treatment
amantadin
recipi
see
fig
thereaft
similar
function
recoveri
reduct
symptom
viral
shed
occur
group
fewer
sideeffect
rinlantadin
recipi
anoth
studi
use
modifi
load
regimen
patient
receiv
mg
rimantadin
first
hour
found
rapid
reduct
viral
titer
fever
compar
placebo
treatment
children
influenza
rimantadin
associ
rapid
symptom
improv
defervesc
compar
acetaminophen
one
aerosol
rimantadin
treatment
experiment
induc
influenza
infect
effect
compar
mg
per
day
rimantadin
rimantadin
expect
licens
oral
use
unit
state
near
futur
indic
clinic
use
amantadin
see
tabl
ribavirin
carboxamid
synthet
nucleosid
analog
guanosin
fig
antivir
spectrum
includ
varieti
dna
rna
virus
particular
influenza
b
parainfluenza
rsv
agent
would
clinic
applic
seriou
ill
inay
caus
virus
clinic
featur
distinct
enough
allow
etiolog
diagnosi
limit
effect
concern
regard
hematolog
toxic
ribavirin
given
oral
recent
studi
focus
aerosol
administr
sever
differ
mechan
antivir
action
r
oo
e
r
b
ai
r
n
ribavirin
monophosph
act
feedback
inlibiior
inosin
monophosph
dehydrogenas
enzym
respons
synthesi
guanin
ribavirin
triphosph
inhibit
step
cap
elong
messeng
rna
certain
appear
directli
interfer
influenza
viru
rna
polymeras
complex
certain
test
system
ribavirin
concentr
pg
per
ml
inhibit
cellular
macromolecular
synthesi
cell
growth
lymphocyt
prolif
respons
ribavirin
addit
biolog
activ
includ
inhibit
humor
antibodi
respons
antitumor
effect
preclin
studi
per
cent
plaqu
inhibitori
concentr
ribavirin
rang
approxim
pg
per
ml
influenza
b
pg
per
ml
respiratori
syncyti
virus
rsv
pg
per
ml
parainfluenza
virus
plaqu
reduct
assay
canin
kidney
mdck
cell
influenza
virus
appear
less
sensit
ribavirin
yield
reduct
assay
primari
rhesu
monkey
kidney
cell
ribavirin
appear
activ
rimantadin
aerosol
ribavirin
initi
hour
infect
mice
significantli
lower
viru
titer
prevent
pneumonia
experiment
influenza
infect
wherea
similar
benefici
effect
observ
aerosol
amantadin
rimantadin
rel
brief
aerosol
exposur
hour
twice
daili
high
concentr
ribavirin
provid
protect
compar
observ
longer
treatment
hour
per
day
threefold
lower
concentr
ferret
treat
ribavirin
subsequ
infect
influenza
viru
develop
typic
febril
reaction
serum
local
antibodi
lower
viru
titer
nasal
wash
untreat
recent
studi
shown
intraven
administr
liposomeencapsul
ribavirin
effect
treatment
experiment
murin
influenza
higher
dose
free
ribavirin
given
high
dose
embryotox
rabbit
rat
teratogen
rat
develop
resist
observ
treatment
human
infect
aerosol
ribavirin
passag
rsv
presenc
inhibitori
concentr
ribavirin
select
virus
resist
drug
limit
inform
avail
concern
pharmacokinet
ribavirin
lack
routin
mean
measur
bv
radioimmunoassay
plasma
halflif
averag
approxim
hour
rang
hour
use
oral
administ
label
ribavirin
found
per
cent
dose
excret
radioact
concentr
red
blood
cell
appar
halflif
day
approv
use
ribavirin
viral
respiratori
diseas
unit
state
current
limit
administr
smallparticl
aerosol
treatment
rsv
infect
gener
design
produc
particl
aerodynam
size
averag
nm
diamet
use
radiolabel
tracer
inhal
aerosol
mist
uninfect
adult
produc
uniform
distribut
per
cent
inhal
particl
throughout
respiratori
tractlog
mean
peak
respiratori
secret
level
pg
per
ml
measur
hour
exposur
children
plasma
concentr
depend
durat
exposur
averag
pg
per
ml
p
g
per
ml
hour
exposur
daili
day
r
ep
e
c
v
e
l
elimin
halflif
ribavirin
respiratori
secret
approxim
oral
ribavirin
administr
associ
revers
decreas
red
blood
cell
count
increas
serum
bilirubin
reticul
oy
like
due
ribavirin
accumul
toxic
circul
red
blood
cell
hematolog
toxic
observ
aerosol
treatment
l
aerosol
administr
report
caus
bronchospasin
adult
preexist
airway
diseas
welltoler
use
treatment
rsv
infect
children
one
case
transient
red
eyelid
describ
presum
due
deposit
drug
skin
potenti
problem
drug
deliveri
system
discuss
next
section
respiratori
syncyti
viru
rsv
ribavirin
small
particl
aerosol
effect
treatment
naturallo
rsv
infect
infant
natur
acquir
rsv
lower
respiratori
tract
diseas
ribavirin
given
continu
aerosol
day
caus
rapid
improv
ill
sever
arteri
oxygen
sever
day
treatment
decreas
viral
titer
respiratori
secret
compar
infant
underli
cardiopulmonari
diseas
rsv
lower
respiratori
tract
infect
ribavirin
recipi
experi
similar
clinic
benefit
fig
decreas
viru
titer
respiratori
secret
occur
third
day
infant
rsv
bronchiol
treat
aerosol
ribavirin
hour
daili
day
rapid
recoveri
ill
differ
viru
shed
receiv
recent
studi
infant
bronchiol
treat
aerosol
ribavirin
hour
daili
least
day
found
rapid
declin
respiratori
heart
rate
compar
children
rsv
infect
rsvspecif
ige
iga
antibodi
respons
develop
less
frequent
nasopharyng
secret
treatment
aerosol
ribavirin
compar
untreat
longterm
benefit
consequ
use
ribavirin
treatment
rsv
infect
determin
specif
gener
unit
requir
administr
aerosol
exposur
given
hour
per
day
day
use
reservoir
concentr
gm
per
ml
achiev
hourli
dose
approxim
mg
per
kg
per
h
usual
daili
dosag
ribavirin
cost
hospit
pharmaci
treatment
cost
may
exceed
per
day
respiratori
therapi
charg
includ
consensu
regard
infant
receiv
newli
avail
therapi
reach
winter
rsv
epidem
therapi
might
appropri
ill
consist
rsv
infant
one
highrisk
group
congenit
heart
diseas
pulmonari
hypertens
bronchopulmonari
dysplasia
sever
combin
immunodefici
syndrom
cystic
fibrosi
anoth
potenti
indic
therapi
group
presum
rsvinfect
infant
manifest
progress
deterior
like
result
intub
candid
includ
pao
level
lower
mm
hg
rise
pa
case
ribavirin
could
start
await
result
rapid
viral
diagnost
test
controversi
earli
use
rsvinfect
infant
serious
compromis
infant
alreadi
ventil
may
becom
clog
drugll
use
inlin
filter
may
amelior
problem
precipit
also
report
deliveri
drug
infant
receiv
oxygen
reason
frequent
routin
check
tube
equip
esenti
anoth
concern
current
studi
contamin
environ
possibl
exposur
hospit
personnel
ribavirin
recent
studi
found
ribavirin
urin
sera
p
e
ro
n
n
e
l
influenza
prophylact
oral
administr
ribavirin
mg
per
day
reduc
ill
sever
viru
titer
experiment
influenza
infect
dose
begin
within
hour
onset
symptom
clinic
benefit
inhibitori
effect
viral
shed
natur
influenza
prophylact
oral
ribavirin
mg
per
day
margin
effect
experiment
influenza
activ
influenza
infectin
aerosol
ribavirin
provid
therapeut
benefit
young
adult
uncompl
influenza
b
viru
infect
start
within
hour
symptom
given
colleg
student
hour
first
day
hour
daili
next
day
aerosol
ribavirin
associ
signific
reduct
height
durat
fever
system
symptom
viru
shed
compar
placebo
aerosol
averag
dose
ribavirin
gm
hour
studi
compar
therapeut
activ
aerosol
ribavirin
oral
amantadin
rimantadin
done
use
aerosol
therapi
requir
hospit
special
equip
treatment
uncompl
influenza
infect
appear
limit
patient
influenza
pneumonia
due
influenza
type
b
treat
aerosol
ribavirin
log
control
trial
need
highrisk
group
respiratori
virus
aerosol
interferon
regulatori
protein
afiect
varieti
host
cell
function
includ
cell
growth
immun
respons
inhibit
viru
replic
particular
protein
capabl
induc
broad
spectrum
antivir
activ
includ
respiratori
virus
name
princip
cellular
sourc
human
interferon
current
classifi
specif
molecular
type
alpha
interferon
formerli
leukocyt
includ
speci
beta
interferon
formerli
fibroblast
least
one
speci
appear
share
cellular
receptor
alpha
interferon
gamma
immun
interferon
lymphokin
deriv
stimul
lymphocyt
molecular
weight
alpha
beta
interferon
approxim
dalton
unavail
suffici
quantiti
pure
interferon
initi
research
emphas
use
chemic
interferon
induc
experi
gener
unsuccess
owe
problem
inadequ
vivo
induct
interferon
instanc
poor
toler
advanc
genet
engin
techniqu
past
decad
howev
becom
possibl
produc
larg
amount
purifi
interferon
recent
studi
shown
intranas
administr
recombin
interferonalpha
effect
prevent
experiment
natur
rhinoviru
exact
mechan
interferon
induc
antivir
state
host
cell
fulli
interferon
induc
format
sever
antivir
protein
target
cell
inhibit
translat
viral
messeng
rna
interferon
exposur
activ
enzym
soligoadenyl
synthetas
produc
oligoadenyl
turn
activ
endonucleas
capabl
degrad
viral
mrna
addit
interferon
activ
protein
kinas
catalyz
phosphoryl
subunit
initi
factor
eif
therebi
inhibit
initi
viral
protein
synthesi
certain
virus
inhibit
matur
assembl
appear
occur
detail
studi
mice
determin
particular
gene
product
mx
protein
confer
select
resist
influenza
viru
infect
interferon
interferon
broadest
antivir
spectrum
current
agent
concentr
unit
beta
interferon
activ
mani
adenoviru
antivir
activ
interferon
usual
speciesspecif
human
interferon
studi
extens
anim
model
use
human
interferon
hybrid
activ
mous
cell
aerosol
interferon
found
limit
efficaci
experiment
murin
influenza
interferon
concentr
determin
biolog
measur
inhibit
viral
replic
plaqu
yield
reduct
techniqu
viru
specif
metabol
protein
product
rna
synthesi
virusinduc
cytopath
effect
addit
immunoassay
avail
measur
concentr
specif
interferon
interferon
act
princip
host
cell
would
expect
viral
resist
would
develop
use
resist
recogn
interferon
treatment
nonrespiratori
v
rs
e
studi
interferon
prevent
respiratori
infect
use
intranas
deliveri
hope
achiev
local
antivir
effect
avoid
system
toxic
initi
halflif
intranas
interferon
antivir
effect
persist
least
concentr
depend
antivir
effect
rapid
nasal
clearanc
may
explain
necess
high
dosag
achiev
protect
clinic
trial
intervent
maintain
higher
local
concentrationssuch
use
oral
antihistamin
decreas
clearanc
satur
cotton
pledgetsreduc
amount
interferon
necessari
achiev
antivir
r
b
b
l
v
limit
clinic
valu
furthermor
shown
beta
interferon
may
directli
inactiv
nasal
secret
variabl
concentr
unit
per
ml
found
nasal
wash
intranas
applic
alpha
interferon
relationship
level
clinic
efficaci
establish
contrast
multipl
advers
effect
parenter
interferon
observ
system
toxic
intranas
interferon
transient
leukopenia
high
dosesthat
million
unit
mu
per
day
greaterand
subiect
mucos
b
n
r
l
e
nasal
intoler
major
limit
factor
intranas
use
recombin
natur
alpha
interferon
occurr
symptom
nasal
dryness
obstruct
discomfort
bloodting
mucu
sign
mucos
friabil
bleed
site
eros
ulcer
nasal
examin
depend
dose
durat
use
symptom
nasal
irrit
report
shortterm
use
highdos
mu
per
day
day
longterm
use
lowdos
mu
per
day
week
alpha
interferon
histolog
studi
document
moder
sever
subepitheli
chronic
inflamrnatin
revers
chang
occur
within
day
initi
treatment
appear
relat
immunolog
effect
interferon
recent
longterm
studi
recombin
beta
interferon
indic
better
toler
alpha
interferon
compar
dosag
one
potenti
problem
use
intranas
interferon
develop
antiinterferon
antibodi
limit
attempt
thu
far
fail
detect
antibodi
nasal
secret
addit
studi
need
therapi
would
expect
use
repetit
prolong
basi
develop
circul
antiinterferon
antibodi
intranas
administr
observ
infrequ
rhinoviru
intranas
administr
natur
recombin
alpha
interferon
effect
prevent
experiment
induc
rhinoviru
cold
level
protect
depend
interferon
dosag
durat
administr
prior
viru
challeng
shortterm
administr
high
dose
mu
per
day
protect
ill
defin
occurr
cold
measur
mucu
product
infect
determin
viru
isol
andor
seroconveri
n
lower
dosag
mu
per
day
allow
infect
take
place
protect
l
n
es
l
dosag
permit
subclin
infect
occur
would
desir
could
allow
develop
natur
immun
subsequ
infect
efficaci
alpha
interferon
prevent
natur
rhinoviru
cold
evalu
season
prophylaxi
studi
interferon
given
period
sever
week
ten
mu
daili
provid
high
level
protect
rhinoviru
infect
associ
unaccept
degre
nasal
lower
daili
dose
mu
per
day
caus
signific
reduct
per
cent
rhinoviru
infect
compar
placebo
nasal
sideeffect
still
occur
per
cent
recipi
anoth
approach
shortterm
use
interferon
exposur
close
contact
upper
respiratori
ill
recent
studi
use
mu
per
day
day
postexposur
prophylaxi
famili
member
found
nearli
per
cent
reduct
total
respiratori
ill
per
cent
reduct
rhinovirusspecif
ill
fig
anoth
studi
found
per
cent
reduct
definit
respiratori
ill
overal
per
cent
ill
reduct
expos
r
h
n
v
rs
howev
benefici
effect
prophylact
strategi
appear
limit
rhinoviru
infect
influenza
parainfluenza
viru
infect
prevent
dosag
see
subsequ
discuss
interferon
gener
welltoler
use
manner
respiratori
virus
limit
evid
suggest
interferon
may
effect
infect
caus
coronaviru
respons
per
cent
common
cold
alpha
interferon
u
per
day
significantli
protect
experiment
coronaviru
infect
ill
littl
effect
volunt
lack
antibodi
challeng
lower
dosag
mu
per
day
protect
ill
allow
subclin
infect
howev
effect
natur
occur
coronaviru
ill
observ
low
dosag
season
familybas
prophylaxi
studi
experiment
influenza
viru
infect
alpha
interferon
mu
per
day
reduc
frequenc
sever
ill
number
day
viral
wherea
studi
use
lower
dose
found
less
clinic
benefit
season
prophylaxi
studi
appar
reduct
infect
due
influenza
parainfluenza
observ
alpha
interferon
therefor
present
time
major
util
interferon
respiratori
viral
diseas
appear
use
shortterm
dose
strategi
prevent
rhinoviru
cold
studi
need
determin
optim
dose
schedul
method
administr
effect
group
increas
risk
complic
respiratori
viral
infect
need
exist
addit
antivir
agent
expand
spectrum
diminish
toxic
increas
eas
use
sever
new
agent
result
excit
advanc
molecular
biolog
vari
stage
investig
may
clinic
use
agent
histor
interest
virucid
agent
capabl
caus
contact
inactiv
viral
infect
import
practic
applic
use
interrupt
transmiss
infect
experiment
condit
paper
handkerchief
impregn
virucid
agent
citric
acid
malic
acid
effect
block
transmiss
rhinoviru
regular
paper
handkerchief
applic
virucid
substanc
iodin
disinfect
contamin
fomit
prior
fingertip
contact
also
reduc
risk
rhinoviru
transmiss
experiment
condit
approach
consider
potenti
valu
yet
proven
effect
natur
condit
ascorb
acid
vitamin
c
ascorb
acid
espous
treatment
prevent
common
cold
vitro
data
specif
antivir
effect
lack
data
recent
control
clinic
trial
indic
neglig
earlier
studi
confound
inadequ
blind
potenti
bia
report
zinc
zinc
chlorid
mm
shown
significantli
inhibit
rhinoviru
plaqu
format
hela
cell
eight
nine
serotyp
howev
zinc
glucon
zinc
salt
concentr
result
minim
reduct
viru
yield
modest
delay
viru
cytopath
effect
cell
cultur
wherea
slightli
higher
concentr
c
tx
c
one
clinic
studi
report
zinc
glucon
lozeng
mg
dissolv
mouth
eight
time
daili
onset
cold
symptom
result
signific
reduct
svmdtom
natur
u
l
howev
lozeng
distinguish
placebo
virolog
analysi
perform
recent
studi
zinc
glucon
lozeng
mg
taken
eight
time
daili
fail
show
clinic
antivir
effect
experiment
rhinoviru
infet
anoth
placebocontrol
trial
use
zinc
acet
lozeng
mg
dissolv
mouth
six
eight
time
daili
found
benefici
effect
symptom
natur
flavon
isol
chines
medicin
herb
select
inhibit
rhinoviru
coxsackieviru
replic
poorli
absorb
gastrointestin
ro
chalcon
deriv
compound
specif
inhibit
per
cent
rhinoviru
type
test
concentr
pg
per
inhibit
appear
mediat
bind
viru
phosphat
ester
ro
wellabsorb
gastrointestin
tract
convert
activ
chalcon
achiev
suffici
level
chalcon
resiratorv
tract
clinic
trial
shown
prophylact
activ
man
despit
demonstr
blood
level
parent
activ
compound
undetect
nasal
wash
specimen
result
illustr
import
achiev
adequ
antivir
concentr
site
infect
respiratori
tract
cell
organ
cultur
enviroxim
isopropyl
phenyl
keton
oxim
potent
inhibitor
rhinoviru
r
e
p
l
ia
n
appear
inhibit
translat
viral
mrna
given
intranas
spray
concentr
mani
time
higher
inhibitori
rhinoviru
vitro
enviroxim
provid
inconsist
protect
experiment
induc
rhinoviru
associ
nasal
combin
oral
intranas
administr
lead
decreas
cold
symptom
viru
titer
associ
gastrointestin
intranas
enviroxim
modest
therapeut
activ
experiment
rhinoviru
ineffect
treatment
natur
modifi
deriv
enviraden
undergo
investig
new
cyclononan
hydrochlorid
ici
structur
similar
amantadin
better
prophylact
activ
influenza
amantadin
anim
studi
dosag
mg
per
day
per
cent
effect
respect
prevent
ill
follow
experiment
influenza
viru
challeng
treatment
experiment
infect
mg
per
day
result
signific
decreas
viru
shed
clinic
symptom
certain
postchalleng
day
drug
concentr
nasal
secret
appear
sever
time
higher
present
blood
neurolog
gastrointestin
sideeffect
observ
higher
dosag
direct
comparison
made
adamantan
prophylact
therapeut
efficaci
natur
influenza
infect
yet
evalu
potent
new
antipicornavir
agent
phenoxylheptyl
win
inhibit
major
rhinoviru
serotyp
test
concentr
less
pg
per
ml
drug
directli
virucid
bind
viru
capsid
appear
major
effect
uncoat
step
viral
r
e
p
l
c
antivir
agent
effect
oral
parenter
treatment
enterovir
infect
studi
experiment
induc
enteroviru
infect
man
progress
nearli
per
cent
human
rhinoviru
serotyp
share
singl
type
cellular
receptor
recent
effort
direct
develop
agent
block
attach
viru
host
cell
receptor
murin
monoclon
antibodi
direct
cellular
receptor
site
potent
vitro
inhibitor
rhinoviru
repliat
intranas
administr
murin
monoclon
antibodi
provid
partial
protect
experiment
rhinoviru
infect
man
use
agent
capabl
block
attach
viru
host
cell
could
prove
effect
prophylaxi
possibl
treatment
rhinoviru
viral
infect
use
combin
antivir
differ
mode
action
might
allow
broader
spectrum
activ
synergist
enhanc
antivir
effect
prevent
drug
resist
andlor
diminish
toxic
rhinovirus
synergist
antivir
activ
demonstr
vitro
variou
type
interferon
combin
chemic
antirhinovir
addit
synergist
effect
shown
ribavirin
amantadin
rimantadin
influenza
interferon
rimantadin
influenza
r
interferon
ribavirin
influenza
b
r
combin
chemotherapi
warrant
evalu
man
respiratori
virus
continu
major
caus
morbid
mortal
current
avail
chemotherapi
limit
oral
amantadin
uncompl
influenza
aerosol
ribavirin
respiratori
syncyti
viru
rsv
infect
amantadin
also
efficaci
chemoprophylaxi
influenza
viru
infect
rimantadin
similar
clinic
efficaci
better
toler
amantadin
aerosol
ribavirin
may
use
treatment
seriou
respiratori
ill
caus
virus
rsv
intranas
applic
interferon
effect
interrupt
spread
rhinoviru
cold
famili
chronic
use
limit
nasal
toxic
sever
newer
agent
approach
chemoprophylaxi
therapi
differ
stage
clinic
investig
combin
antivir
agent
may
offer
best
therapeut
advantag
adequ
test
man
addit
drug
becom
avail
use
expand
current
avail
agent
rapid
viral
diagnosi
assum
increasingli
import
role
optim
use
